Skip To Main Content
Katharine D. Barnard on Muck Rack

Katharine D. Barnard

As seen in: BMJ Open Diabetes Research & Care, Diabetes Care Magazine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Katharine D.

Contact Katharine D., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

What End Users and Stakeholders Want From Automated Insulin Delivery Systems

|
By Diana Naranjo, Katharine D. Barnard, Sakinah C. Suttiratana, Esti Iturralde
| Diabetes Care Magazine Verified
What End Users and Stakeholders Want From Automated Insulin Delivery Systems Diana Naranjo, Sakinah C. Suttiratana, Esti Iturralde, Katharine D. Barnard, Jill Weissberg-Benchell, Lori Laffel, Korey K. Hood Diabetes Care Nov 2017, 40 (11) 1453-1461; DOI: 10.2337/dc17-0400
Open in Who Shared Issue with article?

Closing the loop overnight at home setting: psychosocial impact for adolescents with type 1 diabetes and their parents

|
By Katharine D. Barnard, Tim Wysocki, Janet Allen, Daniela Elleri
| BMJ Open Diabetes Research & Care Verified
Fear of hypoglycemia, particularly nocturnal, is common1 ,2 and a serious complication of insulin treatment in people with type 1 diabetes mellitus (T1DM).
Open in Who Shared Issue with article?

Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, Pivotal Trial

|
By Jort Kropff, Pratik Choudhary, Sankalpa Neupane, Katharine D. Barnard
| Diabetes Care Magazine Verified
AbstractOBJECTIVE It is known that continuous glucose monitoring (CGM) systems can lower mean glucose compared with episodic self-monitoring of blood glucose. Implantable CGM systems may provide additional benefits.RESEARCH DESIGN AND METHODS We studied the Eversense (Senseonics Inc.) implantable CGM sensor in 71 participants aged 18 years and older with type 1 and type 2 diabetes in a 180-day multinational, multicenter pivotal trial. Participants used the CGM system at home and in the clinic.
Open in Who Shared Issue with article?
See all 4 articles